You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

~ Buy the ZEPZELCA (lurbinectedin) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR ZEPZELCA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ZEPZELCA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT05042934 ↗ Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma Not yet recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2021-09-15 This phase Ib/II trial studies best dose and side effects of lurbinectedin and how well it works with or without irinotecan in treating patients with Ewing sarcoma that has come back (relapsed) or is high risk and has spread to other places in the body (metastatic). Lurbinectedin may decrease chemicals in the body related to Ewing sarcoma, and reducing these chemicals may make the tumor cells more sensitive to irinotecan. Chemotherapy drugs, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving lurbinectedin with or without irinotecan may work better in treating patients with Ewing sarcoma.
NCT05042934 ↗ Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma Not yet recruiting M.D. Anderson Cancer Center Phase 1/Phase 2 2021-09-15 This phase Ib/II trial studies best dose and side effects of lurbinectedin and how well it works with or without irinotecan in treating patients with Ewing sarcoma that has come back (relapsed) or is high risk and has spread to other places in the body (metastatic). Lurbinectedin may decrease chemicals in the body related to Ewing sarcoma, and reducing these chemicals may make the tumor cells more sensitive to irinotecan. Chemotherapy drugs, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving lurbinectedin with or without irinotecan may work better in treating patients with Ewing sarcoma.
NCT05099666 ↗ Lurbinectedin + Doxorubicin In Leiomyosarcoma Not yet recruiting Jazz Pharmaceuticals Phase 1/Phase 2 2022-03-01 This research study involves the study drug lurbinectedin in combination with doxorubicin. This research has two parts. The first part is being done to determine the tolerability of lurbinectedin with doxorubicin in people with soft tissue sarcoma. The second part is a randomized study to determine which is more effective at treating leiomyosarcoma, lurbinectedin with doxorubicin or lurbinectedin alone.
NCT05099666 ↗ Lurbinectedin + Doxorubicin In Leiomyosarcoma Not yet recruiting Massachusetts General Hospital Phase 1/Phase 2 2022-03-01 This research study involves the study drug lurbinectedin in combination with doxorubicin. This research has two parts. The first part is being done to determine the tolerability of lurbinectedin with doxorubicin in people with soft tissue sarcoma. The second part is a randomized study to determine which is more effective at treating leiomyosarcoma, lurbinectedin with doxorubicin or lurbinectedin alone.
NCT05229588 ↗ Lurbinectedin in Patients With Advanced Pancreatic Cancer With DNA Repair Mutations Not yet recruiting Jazz Pharmaceuticals Phase 2 2022-03-01 The purpose of this research is to evaluate the activity and safety of lurbinectedin in adult patients with advanced pancreatic cancer with DNA repair mutations.
NCT05229588 ↗ Lurbinectedin in Patients With Advanced Pancreatic Cancer With DNA Repair Mutations Not yet recruiting HonorHealth Research Institute Phase 2 2022-03-01 The purpose of this research is to evaluate the activity and safety of lurbinectedin in adult patients with advanced pancreatic cancer with DNA repair mutations.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ZEPZELCA

Condition Name

Condition Name for ZEPZELCA
Intervention Trials
Metastatic Soft-tissue Sarcoma 1
Pancreas Cancer 1
Recurrent Ewing Sarcoma 1
Stage IV Lung Cancer AJCC v8 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ZEPZELCA
Intervention Trials
Sarcoma 2
Small Cell Lung Carcinoma 1
Lung Neoplasms 1
Carcinoma, Small Cell 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ZEPZELCA

Trials by Country

Trials by Country for ZEPZELCA
Location Trials
United States 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ZEPZELCA
Location Trials
Georgia 1
Arizona 1
Massachusetts 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ZEPZELCA

Clinical Trial Phase

Clinical Trial Phase for ZEPZELCA
Clinical Trial Phase Trials
Phase 2 1
Phase 1/Phase 2 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ZEPZELCA
Clinical Trial Phase Trials
Not yet recruiting 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ZEPZELCA

Sponsor Name

Sponsor Name for ZEPZELCA
Sponsor Trials
Jazz Pharmaceuticals 3
National Cancer Institute (NCI) 2
M.D. Anderson Cancer Center 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ZEPZELCA
Sponsor Trials
Other 4
Industry 3
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.